Natera, Inc. $NTRA Shares Acquired by Zweig DiMenna Associates LLC

Posted by Stanley Muller on May 30th, 2026

Zweig DiMenna Associates LLC lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 134,800 shares of the medical research company’s stock after buying an additional 2,300 shares during the quarter. Natera makes up approximately 1.9% of Zweig DiMenna Associates LLC’s investment portfolio, making the stock its 14th largest position. Zweig DiMenna Associates LLC owned approximately 0.10% of Natera worth $30,881,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Horizon Investments LLC acquired a new position in shares of Natera during the 3rd quarter worth approximately $32,000. Flagship Harbor Advisors LLC acquired a new position in shares of Natera during the 4th quarter worth approximately $41,000. Sound Income Strategies LLC raised its stake in shares of Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after buying an additional 45 shares during the period. TD Waterhouse Canada Inc. acquired a new position in shares of Natera during the 4th quarter worth approximately $62,000. Finally, AXS Investments LLC acquired a new position in shares of Natera during the 3rd quarter worth approximately $69,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 1,652 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total value of $335,091.68. Following the completion of the sale, the insider directly owned 140,643 shares of the company’s stock, valued at $28,528,026.12. This trade represents a 1.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 482 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $210.49, for a total value of $101,456.18. Following the completion of the sale, the chief financial officer directly owned 57,496 shares of the company’s stock, valued at $12,102,333.04. This trade represents a 0.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 41,356 shares of company stock valued at $8,374,584 over the last 90 days. Insiders own 5.63% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on NTRA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Morgan Stanley reduced their target price on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Robert W. Baird set a $265.00 price objective on Natera in a research note on Friday, May 8th. Wells Fargo & Company increased their price objective on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Finally, BTIG Research reduced their price objective on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research note on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $256.60.

Read Our Latest Analysis on Natera

Key Natera News

Here are the key news stories impacting Natera this week:

Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Natera Stock Up 4.4%

Shares of NASDAQ:NTRA opened at $223.37 on Friday. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $256.36. The stock has a market cap of $31.99 billion, a P/E ratio of -137.04 and a beta of 1.57. The business has a fifty day moving average of $202.37 and a two-hundred day moving average of $215.69.

Natera (NASDAQ:NTRA – Get Free Report) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The business had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. During the same period last year, the company earned ($0.41) EPS. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.